GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » EV-to-EBIT

Greenyn Biotechnology Co (ROCO:6846) EV-to-EBIT : 9.99 (As of May. 16, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Greenyn Biotechnology Co's Enterprise Value is NT$1,809.5 Mil. Greenyn Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$181.1 Mil. Therefore, Greenyn Biotechnology Co's EV-to-EBIT for today is 9.99.

The historical rank and industry rank for Greenyn Biotechnology Co's EV-to-EBIT or its related term are showing as below:

ROCO:6846' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.22   Med: 10.4   Max: 15.53
Current: 10.79

During the past 5 years, the highest EV-to-EBIT of Greenyn Biotechnology Co was 15.53. The lowest was 7.22. And the median was 10.40.

ROCO:6846's EV-to-EBIT is ranked worse than
51.75% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs ROCO:6846: 10.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Greenyn Biotechnology Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$1,860.9 Mil. Greenyn Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$181.1 Mil. Greenyn Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 9.73%.


Greenyn Biotechnology Co EV-to-EBIT Historical Data

The historical data trend for Greenyn Biotechnology Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co EV-to-EBIT Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - 9.27 10.64

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.11 11.61 10.49 10.64 -

Competitive Comparison of Greenyn Biotechnology Co's EV-to-EBIT

For the Biotechnology subindustry, Greenyn Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's EV-to-EBIT falls into.



Greenyn Biotechnology Co EV-to-EBIT Calculation

Greenyn Biotechnology Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1809.465/181.081
=9.99

Greenyn Biotechnology Co's current Enterprise Value is NT$1,809.5 Mil.
Greenyn Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$181.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenyn Biotechnology Co  (ROCO:6846) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Greenyn Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=181.081/1860.8533
=9.73 %

Greenyn Biotechnology Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$1,860.9 Mil.
Greenyn Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$181.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenyn Biotechnology Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines